What we're reading, February 22, 2016: new legislation proposes placing a 3-year moratorium on advertising newly approved drugs; the prevalence and incidence of stroke among young adults has increased significantly; and more women with breast cancer are choosing outpatient mastectomies.
A new bill has been introduced that would place a 3-year moratorium on advertisements for newly approved prescription drugs. The freeze on direct-to-consumer advertising for new drugs would prevent consumers from receiving inaccurate information, according to STAT. In addition, the bill seeks to lower healthcare costs as advertising can inflate costs as consumers are prompted to seek newer, higher-priced medicines. The legislation would allow HHS to waive the moratorium if the ad would have “an affirmative value to public health.”
More young Americans are having strokes with about 10% of all strokes occurring in people between the ages of 18 and 50 years. While the majority of strokes are still happening in older individuals, the incidence and prevalence has increased significantly among younger individuals with obesity being the most likely underlying cause, reported NPR. As chronic conditions, including high blood pressure, diabetes, obesity, and lipid disorders, increased, so has the number of young people hospitalized for stroke.
Not only are more women with breast cancer choosing to have mastectomies, but close to half of them go home the same day. Kaiser Health News reported that data has shown breast cancer treatment has shifted from less invasive surgeries, which is of concern to some advocates. From 2005 to 2013, the rate of mastectomy has increased by 36% and the number of them being performed in outpatient centers with no overnight stay is up 22%.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More